North American Scientific and Theseus Imaging reported that clinical trials of Theseus’ Apomate kit have shown the agent to be effective in the noninvasive imaging of apoptosis, or cell death, associated with cardiac transplant rejection. The kit
North American Scientific and Theseus Imaging reported that clinical trials of Theseus Apomate kit have shown the agent to be effective in the noninvasive imaging of apoptosis, or cell death, associated with cardiac transplant rejection. The kit has been used in nuclear medicine procedures in more than 3500 hospitals across the U.S.
Patients who undergo heart transplants can have up to 15 catheterization procedures during the first year after the surgery to evaluate the immunosuppression medications effectiveness, according to the two companies. Theseus hopes Apomate will contribute equivalent information noninvasively by imaging the functional changes that occur when the body rejects an organ.
North American and Theseus signed a merger agreement in October, which is subject to final due diligence, according to Chatsworth, CA-based NASI. Theseus develops radiopharmaceutical products for in vivo medical imaging.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.